Quarterly report · Q2
4587.TEDINET S100RNSH
Period2023-01-01 → 2023-06-30
Filed2023-08-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Amended by S100S6V5 (2023-11-09).
Key figures · 62
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.4bn | 2023-01-01 → 2023-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥4.5bn | 2023-04-01 → 2023-06-30d | Cons. | Revenue IFRS |
| Revenue | ¥26.9bn | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥5.0bn | 2022-01-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥4.6bn | 2022-04-01 → 2022-06-30d | Cons. | Revenue IFRS |
| Operating income | −¥986m | 2023-01-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥720m | 2023-04-01 → 2023-06-30d | Cons. | Operating profit loss IFRS |
| Operating income | −¥1.7bn | 2022-01-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥499m | 2022-04-01 → 2022-06-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥1.1bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥711m | 2023-04-01 → 2023-06-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥6.7bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥1.6bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥467m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥729m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥480m | 2023-04-01 → 2023-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥7.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥1.1bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥303m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥729m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | −¥480m | 2023-04-01 → 2023-06-30d | Cons. | Profit loss IFRS |
| Net income | ¥7.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥1.1bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | −¥303m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss IFRS |
| Total assets | ¥57.7bn | at 2023-06-30 | Cons. | Assets IFRS |
| Total assets | ¥63.9bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥52.4bn | at 2022-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥26.7bn | at 2023-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥31.8bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥31.0bn | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥32.0bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥24.7bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥25.4bn | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥31.0bn | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥32.0bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥24.7bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥11.2bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥5.2bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥6.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥8.8bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥83m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥493m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥798m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥27.4bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥26.7bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥2.3bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥20.8bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥21.6bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-5.62 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-3.7 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥58.19 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-8.72 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-2.33 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-5.62 | 2023-01-01 → 2023-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-3.7 | 2023-04-01 → 2023-06-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥58.14 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-8.72 | 2022-01-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-2.33 | 2022-04-01 → 2022-06-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 53.8% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 47.0% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 22
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-06-30 | −¥30m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-06-30 | −¥30m |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥1.5bn |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥1.5bn |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥1.2bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥8.0bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥8.0bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥30m |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥228m |
| —segment total | revenue | 2023-01-01 → 2023-06-30 | ¥9.5bn |
| —segment total | revenue external | 2023-01-01 → 2023-06-30 | ¥9.4bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥30m |
| —segment total | segment profit | 2023-01-01 → 2023-06-30 | −¥941m |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥1.1bn |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥1.1bn |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥1.4bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥114m |
| —segment total | revenue | 2022-01-01 → 2022-06-30 | ¥5.0bn |
| —segment total | revenue external | 2022-01-01 → 2022-06-30 | ¥5.0bn |
| —segment total | segment profit | 2022-01-01 → 2022-06-30 | −¥1.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 634
| Item | Context | Value | Unit |
|---|---|---|---|
| Equity IFRS | CurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember | 31020624000 | JPY |
| Equity IFRS | CurrentQuarterInstant | 31020624000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | -1590972000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | -1110932000 | JPY |
| Depreciation and amortization ope cf IFRS | Prior1YTDDuration | 787387000 | JPY |
| Depreciation and amortization ope cf IFRS | CurrentYTDDuration | 1221011000 | JPY |
| Interest and dividend income ope cf IFRS | Prior1YTDDuration | -1049000 | JPY |
| Interest and dividend income ope cf IFRS | CurrentYTDDuration | -5792000 | JPY |
| Interest expenses ope cf IFRS | Prior1YTDDuration | 66104000 | JPY |
| Interest expenses ope cf IFRS | CurrentYTDDuration | 116872000 | JPY |
| Foreign exchange loss gain ope cf IFRS | Prior1YTDDuration | -241433000 | JPY |
| Foreign exchange loss gain ope cf IFRS | CurrentYTDDuration | -270895000 | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | Prior1YTDDuration | 109972000 | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | CurrentYTDDuration | 103231000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1YTDDuration | -135091000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | CurrentYTDDuration | 12060426000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | -210141000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | 33568000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1YTDDuration | 597710000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | CurrentYTDDuration | -1186090000 | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | Prior1YTDDuration | 5204000 | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | CurrentYTDDuration | 2175000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | 215635000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | 208303000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | -396674000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 11171878000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YTDDuration | 1049000 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYTDDuration | 5792000 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -51805000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -91717000 | JPY |
| Income taxes paid ope cf IFRS | Prior1YTDDuration | -56233000 | JPY |
| Income taxes paid ope cf IFRS | CurrentYTDDuration | -2316431000 | JPY |
| Income taxes refund ope cf IFRS | Prior1YTDDuration | 10958000 | JPY |
| Income taxes refund ope cf IFRS | CurrentYTDDuration | － | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | -492704000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 8769521000 | JPY |
| Purchase of investment securities inv cf IFRS | Prior1YTDDuration | － | JPY |
| Purchase of investment securities inv cf IFRS | CurrentYTDDuration | -200000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YTDDuration | -23460335000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYTDDuration | － | JPY |
| Collection of loans receivable inv cf IFRS | Prior1YTDDuration | 65926000 | JPY |
| Collection of loans receivable inv cf IFRS | CurrentYTDDuration | 3121000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YTDDuration | -3218559000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYTDDuration | -547145000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YTDDuration | -58228000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYTDDuration | -53632000 | JPY |
| Other inv cf IFRS | Prior1YTDDuration | -8724000 | JPY |
| Other inv cf IFRS | CurrentYTDDuration | 112000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -26679922000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | -797543000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |